专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06699908B2 Methods for providing safe local anesthesia 失效
标题翻译：方法提供安全的局部麻醉
公开(公告)号：US06699908B2
公开(公告)日：2004-03-02
申请号：US09963256
申请日：2001-09-26
申请人： Richard S. Sackler , Paul D. Goldenheim , Mark Chasin , Ronald M. Burch , Robert F. Reder , Joseph Tigner
发明人： Richard S. Sackler , Paul D. Goldenheim , Mark Chasin , Ronald M. Burch , Robert F. Reder , Joseph Tigner
IPC分类号： A61K31195
CPC分类号： A61K31/445 , A61K9/0024 , A61K9/1647 , A61K31/167 , A61K31/245 , A61K31/47 , Y10S514/818
摘要： Methods and formulations for inducing substantially safer local anesthesia in a patient are provided. The methods comprise administering, to a patient in need thereof, a substrate containing a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material to safely obtain a reversible nerve blockade when implanted or injected in a patient.
摘要翻译：提供了用于在患者体内诱导基本上更安全的局部麻醉的方法和制剂。所述方法包括向需要其的患者施用含有局部麻醉剂和有效量的生物相容的可生物降解的控制释放材料的基质，以在植入或注射入患者时安全地获得可逆神经阻断。

2. 发明申请

US20120252794A1 ANALGESIC COMBINATION OF OPIOID ANALGESIC AND CYCLOOXYGENASE-2 INHIBITOR 审中-公开
标题翻译：阿片类药物和CYCLOOXYGENASE-2抑制剂的分析组合
公开(公告)号：US20120252794A1
公开(公告)日：2012-10-04
申请号：US13461036
申请日：2012-05-01
申请人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
发明人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
IPC分类号： A61K31/485 , A61P25/04 , A61K31/5415
CPC分类号： A61K45/06 , A61K31/135 , A61K31/137 , A61K31/415 , A61K31/4353 , A61K31/485 , A61K31/54 , A61K31/12 , A61K2300/00
摘要： The invention relates to the use of a combination of an opioid analgesic together with a COX-2 inhibitor.
摘要翻译：本发明涉及阿片类止痛剂与COX-2抑制剂的组合的用途。

3. 发明授权

US08685994B2 Analgesic combination of oxycodone and celecoxib 有权
标题翻译：羟考酮和塞来昔布的止痛组合
公开(公告)号：US08685994B2
公开(公告)日：2014-04-01
申请号：US11698394
申请日：2007-01-26
申请人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
发明人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
IPC分类号： A61K31/4353 , A61K31/415
CPC分类号： A61K45/06 , A61K31/135 , A61K31/137 , A61K31/415 , A61K31/4353 , A61K31/485 , A61K31/54 , A61K31/12 , A61K2300/00
摘要： Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient an oral dosage form comprising two analgesic compounds consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.
摘要翻译：公开了一种药物组合物，其包含由塞来昔布和/或其至少一种药学上可接受的盐和羟考酮和/或其至少一种药学上可接受的盐组成的两种镇痛化合物和/或其药学上可接受的盐，所述两种止痛化合物的量足以在人类患者中提供镇痛作用。还公开了一种有效治疗人类或其他哺乳动物疼痛的方法，其包括向患者口服给予口服剂型，其包含由塞来昔布和/或其至少一种药学上可接受的盐组成的两种镇痛化合物和羟考酮和/或至少一种其药学上可接受的盐，所述两种镇痛化合物的量足以在人类患者中提供镇痛作用。

4. 发明授权

US08193209B2 Analgesic combination of oxycodone and meloxicam 有权
标题翻译：羟考酮与美洛昔康的止痛组合
公开(公告)号：US08193209B2
公开(公告)日：2012-06-05
申请号：US10056347
申请日：2002-01-25
申请人： Ronald M. Burch , Richard S. Sackler , Paul D. Goldenheim
发明人： Ronald M. Burch , Richard S. Sackler , Paul D. Goldenheim
IPC分类号： A61K31/485
CPC分类号： A61K45/06 , A61K31/135 , A61K31/137 , A61K31/415 , A61K31/4353 , A61K31/485 , A61K31/54 , A61K31/12 , A61K2300/00
摘要： Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of meloxicam and/or at least one a pharmaceutically acceptable salt thereof and a dose oxycodone and/or at least one a pharmaceutically acceptable salt thereof, the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a an oral dosage form comprising two analgesic compounds consisting of meloxicam and/or at least one a pharmaceutically acceptable salt thereof and oxycodone and/or at least one a pharmaceutically acceptable salt thereof, the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.
摘要翻译：公开了一种药物组合物，其包含由美洛昔康和/或其至少一种药学上可接受的盐和剂量羟考酮和/或其至少一种药学上可接受的盐组成的两种镇痛化合物和/或其药学上可接受的盐，两种止痛剂化合物的量足以在人类患者中提供镇痛作用。还公开了一种有效治疗人类或其它哺乳动物疼痛的方法，其包括向患者施用口服剂型，其包含由美洛昔康和/或其至少一种药学上可接受的盐和羟可待酮组成的两种止痛化合物和/或至少一种其药学上可接受的盐，两种镇痛化合物的量足以在人类患者中提供镇痛作用。

5. 发明授权

US08188107B2 Analgesic combination of oxycodone and N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide 有权
标题翻译：羟考酮与N- [3-（甲酰氨基）-4-氧代-6-苯氧基-4H-1-苯并吡喃-7-基]甲磺酰胺的镇痛组合
公开(公告)号：US08188107B2
公开(公告)日：2012-05-29
申请号：US10057632
申请日：2002-01-25
申请人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
发明人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
IPC分类号： A61K31/485
CPC分类号： A61K45/06 , A61K31/135 , A61K31/137 , A61K31/415 , A61K31/4353 , A61K31/485 , A61K31/54 , A61K31/12 , A61K2300/00
摘要： Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of N-[3 -(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one a pharmaceutically acceptable salt thereof and a-dose oxycodone and/or at least one a pharmaceutically acceptable salt thereof, the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient a an oral dosage form comprising two analgesic compounds consisting of N-[3-(formylamino)-4-oxo-6 -phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one a pharmaceutically acceptable salt thereof and oxycodone and/or at least one a pharmaceutically acceptable salt thereof such that the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.
摘要翻译：公开了一种药物组合物，其包含两种由N- [3-（甲酰氨基）-4-氧代-6-苯氧基-4H-1-苯并吡喃-7-基]甲磺酰胺和/或其盐的组合的镇痛化合物和/或其药学上可接受的盐其至少一种其药学上可接受的盐和剂量的羟考酮和/或其至少一种药学上可接受的盐，其量足以在人类患者中提供镇痛作用的两种止痛化合物。还公开了一种有效治疗人或其他哺乳动物疼痛的方法，其包括口服给予患者口服剂型，其包含由N- [3-（甲酰氨基）-4-氧代-6-苯氧基-4H -1-苯并吡喃-7-基]甲磺酰胺和/或其至少一种药学上可接受的盐和羟考酮和/或其至少一种药学上可接受的盐，使得两种镇痛化合物的量足以提供镇痛作用一个人的病人。

6. 发明授权

US08168629B2 Analgesic combination of tramadol and meloxicam 有权
标题翻译：曲马多和美洛昔康的止痛组合
公开(公告)号：US08168629B2
公开(公告)日：2012-05-01
申请号：US11825938
申请日：2007-07-10
申请人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
发明人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
IPC分类号： A61K31/54 , A61K31/135
CPC分类号： A61K45/06 , A61K31/135 , A61K31/137 , A61K31/415 , A61K31/4353 , A61K31/485 , A61K31/54 , A61K31/12 , A61K2300/00
摘要： Disclosed is a pharmaceutical composition, comprising a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of tramadol or a pharmaceutically acceptable salt thereof, the combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of tramadol or a pharmaceutically acceptable salt thereof such that the dosing interval of the meloxicam overlaps with the dosing interval of the tramadol, the combination in an amount sufficient to provide an analgesic effect in a human patient.
摘要翻译：公开了一种药物组合物，其包含美洛昔康或其药学上可接受的盐的剂量与曲马多或其药学上可接受的盐的剂量的组合，其量足以在人类患者中提供镇痛作用。还公开了一种有效治疗人或其他哺乳动物疼痛的方法，其包括向患者施用美洛昔康或其药学上可接受的盐的剂量组合以及曲马多或其药学上可接受的盐的剂量，使得给药间隔美洛昔康与曲马多的给药间隔重叠，其量足以在人类患者中提供镇痛作用。

7. 发明授权

US06552031B1 Synergistic analgesic combination of oxycodone and rofecoxib 有权
标题翻译：羟考酮与罗非昔布的止痛组合
公开(公告)号：US06552031B1
公开(公告)日：2003-04-22
申请号：US09154354
申请日：1998-09-17
申请人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
发明人： Ronald M. Burch , Paul D. Goldenheim , Richard S. Sackler
IPC分类号： A01N4342
CPC分类号： A61K45/06 , A61K31/135 , A61K31/137 , A61K31/415 , A61K31/4353 , A61K31/485 , A61K31/54 , A61K31/12 , A61K2300/00
摘要： Disclosed is a pharmaceutical composition, comprising a combination of a dose of rofecoxib or a pharmaceutically acceptable salt thereof and a dose of oxcodone or a pharmaceutically acceptable salt thereof, said combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a combination of a dose of rofecoxib or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof such that the dosing interval of the rofecoxib overlaps with the dosing interval of the oxycodone, said combination in an amount sufficient to provide an analgesic effect in a human patient.
摘要翻译：公开了一种药物组合物，其包含罗非考昔或其药学上可接受的盐的剂量和羟考酮或其药学上可接受的盐的剂量的组合，所述组合的量足以在人类患者中提供镇痛作用。还公开了一种有效治疗人类或其他哺乳动物疼痛的方法，其包括向患者施用罗非考昔或其药学上可接受的盐的剂量和一定剂量的羟考酮或其药学上可接受的盐，使得给药间隔罗非昔布与羟考酮的给药间隔重叠，所述组合的量足以在人类患者中提供镇痛作用。

8. 发明授权

US07083808B2 Controlled/modified release oral methylphenidate formulations 有权
标题翻译：对照/改良口服哌甲酯制剂
公开(公告)号：US07083808B2
公开(公告)日：2006-08-01
申请号：US10741081
申请日：2003-12-19
申请人： Paul D. Goldenheim , Richard S. Sackler , Thinnayam N. Krishnamurthy , Andrew Darke , Benjamin Oshlaci
发明人： Paul D. Goldenheim , Richard S. Sackler , Thinnayam N. Krishnamurthy , Andrew Darke , Benjamin Oshlaci
IPC分类号： A61K9/14 , A61K9/16 , A61K9/22 , A61K9/48 , A61K9/52
CPC分类号： A61K31/4458 , A61K9/1676 , A61K9/2027 , A61K9/2054 , A61K9/5026 , A61K9/5078 , A61K9/5084
摘要： The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
摘要翻译：本发明涉及口服改良/控释哌甲酯制剂，其提供快速起效和起效延长。优选地，峰浓度低于立即释放哌甲酯制剂的参考标准提供的峰值浓度，并且效果持续时间在给药间隔结束时迅速下降，以免影响患者在晚餐时的胃口和患者的睡眠之后

9. 发明授权

US06673367B1 Controlled/modified release oral methylphenidate formulations 有权
标题翻译：对照/改良口服哌甲酯制剂
公开(公告)号：US06673367B1
公开(公告)日：2004-01-06
申请号：US09465158
申请日：1999-12-16
申请人： Paul D. Goldenheim , Richard S. Sackler , Thinnayam N. Krishnamurthy , Andrew Darke , Benjamin Oshlack
发明人： Paul D. Goldenheim , Richard S. Sackler , Thinnayam N. Krishnamurthy , Andrew Darke , Benjamin Oshlack
IPC分类号： A61K920
CPC分类号： A61K31/445 , A61K9/1617 , A61K9/1635 , A61K9/1652 , A61K9/1676 , A61K9/1694 , A61K9/2027 , A61K9/205 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/4458
摘要： The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.
摘要翻译：本发明涉及口服改良/控释哌甲酯制剂，其提供快速起效和起效延长。优选地，峰浓度低于立即释放哌甲酯制剂的参考标准提供的峰值浓度，并且效果持续时间在给药间隔结束时迅速下降，以免影响患者在晚餐时的胃口和患者的睡眠之后

10. 发明申请

US20110288112A1 Method of Providing Sustained Analgesia With Buprenorphine 审中-公开
标题翻译：提供丁丙诺啡持续镇痛的方法
公开(公告)号：US20110288112A1
公开(公告)日：2011-11-24
申请号：US12888298
申请日：2010-09-22
申请人： Robert F. Reder , Paul D. Goldenheim , Robert F. Kaiko
发明人： Robert F. Reder , Paul D. Goldenheim , Robert F. Kaiko
IPC分类号： A61K31/46
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
摘要翻译：通过在最初的三天给药间隔内按照一级动力学施用丁丙诺啡以达到达到约20pg / ml至约1052pg / ml的最大血浆浓度，实现了有效治疗人类疼痛的方法，以及此后根据基本零级动力学维持丁丙诺啡至少另外两天给药间隔的施用，使得患者在整个至少两天的额外给药间隔期间经历止痛。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式